Drug Review: Eflapegrastim

PTB Reports, 2023, 9, 2, 52-53.
DOI: 10.5530/PTB.2023.9.8
Published: November 2023
Type: Drug Review
Authors:
Juman Alsaab

Author(s) affiliations:

Juman Alsaab, Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

Registrations: It had been registered in the following countries: United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (S.A.) Trade name (USA); ROLVEDON Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (29.1.2023). General Information: Registered Company: Spectrum Pharmaceuticals. Regulatory Status: R.X. Mechanism of Action: A recombinant human granulocyte growth factor activates signaling pathways that affect cell differentiation, proliferation, migration, and survival by binding to G-CSF receptors on myeloid progenitor cells and neutrophils.

View: DOWNLOAD PDF  | DOWNLOAD SLIDE